Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed operable stage IIA, IIB, or IIIA adenocarcinoma of the breast with histologically involved lymph nodes (T1, 2, or 3; N1 or 2; M0) OR high-risk node-negative disease (T2 or 3; N0)~  * Primary tumor at least 2.1 cm in diameter for node-negative disease~ * Bilateral breast disease allowed if at least 1 primary tumor meets the criteria above~* Must have had at least 6 axillary lymph nodes removed at dissection and at least one node positive for metastasis OR~* Sentinel node biopsy negative for metastasis (sentinel node biopsy positive allowed if enrolled on American College of Surgery Trial Z0011 and have beenrandomized to receive no axillary dissection)~  * Additional axillary nodes may be obtained provided they are also negative for metastasis~* Complete tumor removal by either a modified radical mastectomy or local excision plus axillary lymph node dissection (i.e., breast conservation therapy) or sentinel node biopsy~  * Tumor-free margins at least 1 mm for both invasive and noninvasive carcinoma except for lobular carcinoma in situ (less than 1 mm allowed)~* Concurrent enrollment on American College of Surgery Trial Z0010, Z0011, or NSABP B-32 allowed~* Hormone receptor status:~  * Estrogen receptor status positive, negative, or unknown~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Sex:~* Female~Menopausal status:~* Not specified~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* Neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 1.5 mg/dL~* SGOT no greater than 2 times upper limit of normal~Renal:~* Creatinine no greater than 1.5 mg/dL~Cardiovascular:~* No history of myocardial infarction~* No congestive heart failure~* No significant ischemic or valvular heart disease~Other:~* No other prior invasive malignancies within the past 5 years except curatively treated basal or squamous cell skin cancer or carcinoma in situ of the cervix~* No hypersensitivity to paclitaxel or docetaxel or other similarly formulated drugs (with Cremophor or polysorbate)~* Not pregnant or nursing~* Fertile patients must use effective barrier contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy for breast cancer~Endocrine therapy:~* Prior tamoxifen of no more than 4 weeks duration for breast cancer allowed~* Prior tamoxifen or other selective estrogen receptor modulator (SERM) for chemoprevention (e.g., Breast Cancer Prevention Trial) or for other indications (e.g., osteoporosis) allowed~* No concurrent tamoxifen or other SERMs~Radiotherapy:~* No prior radiotherapy for this malignancy~* At least 2 weeks since prior radiotherapy to the breast for ductal carcinoma in situ~Surgery:~* See Disease Characteristics~* Less than 84 days since prior surgical procedure to adequately treat primary tumor

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete